These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 29104025)

  • 1. Breast cancer genomics and immuno-oncological markers to guide immune therapies.
    Hammerl D; Smid M; Timmermans AM; Sleijfer S; Martens JWM; Debets R
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):178-188. PubMed ID: 29104025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
    Curigliano G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
    Luen SJ; Savas P; Fox SB; Salgado R; Loi S
    Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.
    de la Cruz-Merino L; Chiesa M; Caballero R; Rojo F; Palazón N; Carrasco FH; Sánchez-Margalet V
    Int Rev Cell Mol Biol; 2017; 331():1-53. PubMed ID: 28325210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
    Engels CC; Charehbili A; van de Velde CJ; Bastiaannet E; Sajet A; Putter H; van Vliet EA; van Vlierberghe RL; Smit VT; Bartlett JM; Seynaeve C; Liefers GJ; Kuppen PJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):587-96. PubMed ID: 25616355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the role of immunotherapy in breast cancer?
    Tan TJ; Chan JJ; Kamis S; Dent RA
    Chin Clin Oncol; 2018 Apr; 7(2):13. PubMed ID: 29764158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
    Dieci MV; Radosevic-Robin N; Fineberg S; van den Eynden G; Ternes N; Penault-Llorca F; Pruneri G; D'Alfonso TM; Demaria S; Castaneda C; Sanchez J; Badve S; Michiels S; Bossuyt V; Rojo F; Singh B; Nielsen T; Viale G; Kim SR; Hewitt S; Wienert S; Loibl S; Rimm D; Symmans F; Denkert C; Adams S; Loi S; Salgado R;
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):16-25. PubMed ID: 29024776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
    Burugu S; Asleh-Aburaya K; Nielsen TO
    Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of cancer/testis antigens (CTAs) in breast cancer.
    Li Y; Li J; Wang Y; Zhang Y; Chu J; Sun C; Fu Z; Huang Y; Zhang H; Yuan H; Yin Y
    Cancer Lett; 2017 Jul; 399():64-73. PubMed ID: 28274891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for metastatic breast cancer.
    Sugie T
    Chin Clin Oncol; 2018 Jun; 7(3):28. PubMed ID: 30056730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genomics and clinical research for breast cancer].
    Bertucci F; Birnbaum D
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing Immunotherapy in Metastatic Breast Cancer.
    Mansour M; Teo ZL; Luen SJ; Loi S
    Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-based breast cancer immunotherapy.
    Pilipow K; Darwich A; Losurdo A
    Semin Cancer Biol; 2021 Jul; 72():90-101. PubMed ID: 32492452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Kochi M; Iwamoto T; Niikura N; Bianchini G; Masuda S; Mizoo T; Nogami T; Shien T; Motoki T; Taira N; Tokuda Y; Doihara H; Matsuoka J; Fujiwara T
    Breast Cancer Res Treat; 2018 Jan; 167(1):39-47. PubMed ID: 28905250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.
    Morfouace M; Hewitt SM; Salgado R; Hartmann K; Litiere S; Tejpar S; Golfinopoulos V; Lively T; Thurin M; Conley B; Lacombe D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):158-165. PubMed ID: 29307568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
    Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
    J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.